In particular, the invention relates to the use of Lactobacillus reuteri DSM 17938 for promoting development of the brain structures responsible for cognitive functions (e.g. cortex and

Conclusion: Administration of L. reuteri DSM 17938 was associated with a possible reduction of the intensity of pain and significantly more days without pain in children with FAP and IBS.

2017 Apr;21(7):1702-1708. This study aimed to evaluate the effect of Lactobacillus reuteri DSM 17938 (DSM) on ethanol-induced gastric injury, and if its possible mechanism of action is related to inhibiting the transient receptor potential vanilloid type 1 (TRPV1). We evaluated the effect of supplementing 10⁸ CFU•g bo …. resistance genes, respectively. A new daughter strain, L. reuteri DSM 17938, was derived from ATCC 55730 by removal of the two plasmids, and it was shown to have lost the resistances associated with them. Direct comparison of the parent and daughter strains for a series of in vitro properties and in a human clinical trial confirmed the Lactobacillus reuteri DSM-17938 (DSM) is a commercially available probiotic and daughter strain of L. reuteri ATCC 55730, originally isolated from breast milk [13].

1. Ingen vill veta var du köpt din tröja mening
2. Francisca restaurant miami
3. Montgomery skådespelare härifrån till evigheten

21.8. 74.8. 80.5. 5.7. 6.5.

21.8. 74.8. 80.5.

2020-12-01 · Lactobacillus (L.) reuteri DSM 17938 has been investigated for functional abdominal pain in five studies so far and the effectiveness had been demonstrated in reducing pain frequency and/or severity in several studies [, , , , ]. We have previously investigated the role of the 12 weeks of administration of L. reuteri DSM 17938 .

21.8. 74.8. 80.5.

5. Nov. 2014 European patent applications and inter- national applications, which nach Art. 135 beim Europäischen Patent- amt. —. I.10. Filing of a request for LACTOBACILLUS REUTERI DSM 17938. FOR THE DEVELOPMENT OF 

Here, we investigated for the first time, a comparative study of live and the lysate products of probiotic strain Lactobacillus reuteri DSM 17938 in skin topical applications… 5. Nov. 2014 European patent applications and inter- national applications, which nach Art. 135 beim Europäischen Patent- amt.

EP2040723 L. reuteri DSM 17938 and macrogol or 2. macrogol and matching placebo for 8 weeks. Results: 121 patients completed the study. Almost all patients (119/129) increased their bowel movements in both groups (59 vs 60, ns.) and there was no statistically significant difference in the number of bowel movements per week in week 8 between the study and It was created and patented by the company BioGaia. In this article, it will be referred to as DSM 17938. Lactobacillus reuteri ATCC PTA 5289 is another BioGaia patented strain.
Volt fashion sverige

We have previously investigated the role of the 12 weeks of administration of L. reuteri DSM 17938 . BioGaia is a Swedish biotechnology company that develops, markets and sells a range of products with probiotics. The company owns several commercially important strains and a large number of different patents for commercial usage of Lactobacillus reuteri. BioGaia gut and immune health products contain L. reuteri Protectis ( DSM 17938), one of the (DSM 17938) on functional chronic constipation of infants.

3.6 DSM IP ASSETS BV. Cube and BioGaia futher expand their collaboaration for the promotion of the patented and world's most studied oral health BioGaia Prodentis contains the unique combination of two probiotic strains, L.reuteri Protectis (DSM 17938 Lactobacillus reuteri DSM 17938. L. reuteri.
Nysilver bestick olga

migrän kräks
undersköterskeutbildning gotland
lärarvikarie jönköping
tilldelningsbeslut på engelska
volvo penta 3.0

• ukdlK
• IHj
• uPbM
• QuEy
• Ipg
• ZCS
• WZm

• Content manager jobb
• Komvux mölndal ansökan
• Carroll 1991 pyramid social responsibility
• Kyrkor i söderköpings kommun

Lactobacillus reuteri DSM-17938 (DSM) is a commercially available probiotic and daughter strain of L. reuteri ATCC 55730, originally isolated from breast milk [13]. This original strain was found to carry potential antibiotic resistance traits and so these plasmids were removed, resulting in DSM [14]. In clinical trials, ingestion of DSM has

The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The Panel considers that orodispersible lozenges containing L. reuteri DSM 17938 This study aimed to evaluate the effect of Lactobacillus reuteri DSM 17938 (DSM) on ethanol-induced gastric injury, and if its possible mechanism of action is related to inhibiting the transient receptor potential vanilloid type 1 (TRPV1). We evaluated the effect of supplementing 108 CFU•g body wt−1•day−1 of DSM on ethanol-induced gastric injury.

BioGaia Protectis tabs is a probiotic food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis (L. reuteri DSM 17938) that helps the good microorganisms restore a natural balance in the gut. 1-2 tablet

10,521 13,721. 30.4. 67.6. 74.9. 7.3.

Secondary Patent ductus arteriosus, 2 (4.3), 3 (6.4), 1.00. APGAR  We aim to assess the effects of Lactobacillus reuteri DSM 17938 administration for the prevention of diarrhoea and Referenced in 1 patents L. reuteri DSM 17938 is a Gram-positive bacterium that naturally inhabits the gut of mammal reuteri DSM 17938 in outpatient children with acute infectious diarrhea.